Seeking Alpha

Raptor Pharmaceutical (RPTP) meets its primary endpoint in its Phase 3 clinical trial of delayed...

Raptor Pharmaceutical (RPTP) meets its primary endpoint in its Phase 3 clinical trial of delayed release Cysteamine for the treatment of nephropathic cystinosis. Shares, which had climbed as high as 5.5% earlier in the morning, are now +2%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs